Spinal glial activation has been implicated in sustained morphine-mediated paradoxical pain sensitization. Since activation of glial CB2 cannabinoid receptors attenuates spinal glial activation in neuropathies, we hypothesized that CB2 agonists may also attenuate sustained morphine-mediated spinal glial activation and pain sensitization. Our data indicate that co-administration of a CB2-selective agonist (AM 1241) attenuates morphine (intraperitoneal; twice daily; 6 days)-mediated thermal hyperalgesia and tactile allodynia in rats. A CB2 (AM 630) but not a CB1 (AM 251) antagonist mitigated this effect. AM 1241 co-treatment also attenuated spinal astrocyte and microglial marker and pro-inflammatory mediator (IL-1β, TNFα) immunoreactivities in morphine-treated rats, suggesting that CB2 agonists may be useful to prevent the neuroinflammatory consequences of sustained morphine treatment.
Introduction
Long-term opioid treatment frequently leads to an increased sensitivity to painful (hyperalgesia) and normally innocuous (allodynia) stimuli in humans (Arner et al., 1988; Wanigasekera et al., 2011) and in experimental animals (Vanderah et al., 2001b) . It was suggested that long-term opioid-mediated paradoxical pain sensitization may play a role in apparent antinociceptive tolerance (Vanderah et al., 2001a; Ossipov et al., 2005) . However, the molecular mechanisms that lead to paradoxical pain sensitization upon chronic opioid treatment are poorly understood.
Central nervous system (CNS) glia was shown to play an important role in the regulation of pain sensitivity during inflammatory and neuropathic conditions (Watkins et al., 2005) . Interestingly, it was found that -similar to inflammation and nerve injury -sustained opioid agonist-treatment also activates CNS microglia and astrocytes (Watkins et al., 2005 (Watkins et al., , 2007 . Glial proinflammatory inhibitors were shown to attenuate sustained morphine-mediated pain sensitization and to reduce/delay the development of antinociceptive tolerance (Raghavendra et al., 2002 (Raghavendra et al., , 2003 Mika et al., 2007) in experimental animals. The molecular mechanisms leading to sustained opioidmediated augmentation of glial activity and glial pro-inflammatory mediator release are presently not entirely clear. Morphine may directly activate glial opioid receptors (Chang et al., 1998) . Alternatively, it has been suggested that morphine may interact with Toll-like receptors (such as TLR-4) on glial cells (Hutchinson et al., 2007) . Finally, sustained opioid treatment may also activate glial cells indirectly, for instance by stimulating excitatory modulator release from the sensory neurons (Wang et al., 2009 ).
It was suggested that spinal glial activation and glia-derived proinflammatory mediator (such as IL-1β, tumor necrosis factor-α (TNF-α), and prostaglandin E 2 (PGE 2 )) release may be implicated in long-term opioid treatment-mediated paradoxical pain sensitization and antinociceptive tolerance (Watkins et al., 2005) . Therefore, glial E-mail address: evarga@email.arizona.edu (E.V. Varga).
